Company CEO John Huemoeller II Interviewed by Tony Noto on AXIM’s Diagnostic Research Programs in Dry Eye Disease and Parkinson’s SAN DIEGO, CA, March 27, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – AXIM Biotechnologies, Inc . (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, today released a fireside chat interview conducted with its CEO John... Read More

The Company’s Commercialization Partner Verséa Ophthalmic Places Re-stock Order of AXIM’s Digital Assay Reader SAN DIEGO, CA, Feb. 20, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – AXIM Biotechnologies, Inc . (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, announced today that the Company has received an additional order for its electronic readers... Read More

Leading Diagnostic Healthcare Company Signs Contract Manufacturing Agreement in Order to Fulfill Sales of IgE and Lactoferrin DED Diagnostic Assays SAN DIEGO, CA, Dec. 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, announced today that the Company has signed an agreement... Read More

AXIM’s New Assay Uses a Single Tear Drop to Measure abnormal alpha-synuclein, known as the “Parkinson’s Protein” Biomarker, with Results in 8 minutes SAN DIEGO, / Sep 12, 2023 / Business Wire / AXIM Biotechnologies, Inc . (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, announced today that it has successfully developed the world’s first rapid,... Read More

Leading Diagnostic Healthcare Company Highlights Value Proposition of Expanding IP Portfolio Which Includes 13 Different Filings and Allowances SAN DIEGO / Aug 01, 2023 / Business Wire / AXIM Biotechnologies, Inc . (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, announced today the receipt of notification by the United States Patent & Trademark... Read More

Leading Diagnostic Healthcare Company Also Announces Over 50 Initial Clinic Commitments for Its Full Diagnostic Assay Platform SAN DIEGO, CA, July 12, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – AXIM Biotechnologies, Inc . (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, announced today that it has begun shipping revenue generating validation kits... Read More

Leading Diagnostic Healthcare Company Also Announces Over 50 Initial Clinic Commitments for Its Full Diagnostic Assay Platform SAN DIEGO, CA, July 12, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – AXIM Biotechnologies, Inc . (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, announced today that it has begun shipping revenue generating validation kits... Read More

Leading Dry Eye Disease Diagnostic Healthcare Company’s Assays to be Performed in Over 40 Initial Clinics Across US SAN DIEGO, CA, May 24, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – AXIM Biotechnologies, Inc . (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, announced today that through its distribution partner Verseá Ophthalmics it has received... Read More

Leading Diagnostic Healthcare Company Selects Accomplished Operations Executive to Spearhead Growth of Diagnostic Assays Manufacturing SAN DIEGO, CA, May 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- AXIM Biotechnologies, Inc . (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, announced today the appointment of Kurt Phinney as its new Chief... Read More

Leading Diagnostic Healthcare Company Begins Manufacturing of Ocular Immunoglobulin (IgE), Lactoferrin Tests to Fulfill Orders From Commercialization Partner SAN DIEGO, CA, April 11, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- AXIM Biotechnologies, Inc . (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, announced today the start of manufacturing of... Read More

Leading Diagnostic Healthcare Company Announces Provisional Patent Filing on Proprietary Use of Materials for Ophthalmological Test Strip Manufacturing SAN DIEGO, CA, March 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- AXIM Biotechnologies, Inc . (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, announced today the filing of a provisional patent... Read More

Diagnostic Healthcare Solutions Company Developing New Test Designed to Measure Neutralizing Antibodies of Deadly Opioid Fentanyl SAN DIEGO, CA, Jan. 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- AXIM Biotechnologies, Inc . (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, announced today that it has filed a provisional patent application with... Read More

Summary: In 2022, AXIM® finalized optimization of its R&D and manufacturing infrastructure to be used in its diagnostic program AXIM will continue to generate revenue from its two FDA-cleared dry eye disease (DED) diagnostic tests through commercialization partner Verséa Ophthalmics AXIM anticipates its business to be cash-flow positive in the second half of 2023 The Company will place a new strategic focus on custom... Read More

Leading Diagnostic Healthcare Company Announces Development of and Provisional Patent Filing on First-of-Its-Kind Point-of-Care Ophthalmological Diagnostic Solution Enabling Precision Treatment of Common Eye Conditions SAN DIEGO, Dec. 13, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc . ( OTCQB: AXIM ) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company,... Read More